县工商联主席带领民营经济人士赴穆棱市开展考察学习。考察团深入龙穆雅品亚麻纺织有限公司、金泰 恒亚麻有限公司实地走访，围绕亚麻种植地块遴选、轮作模式等技术进行深度交流研讨，助推亚麻产业 发展。主动牵线搭桥，协调黑龙江康利斯药业有限公司负责人前往佳木斯市中药材商会考察调研，搭建 跨区域商会合作对接平台，切实帮助企业拓宽产品销售渠道。 为破解企业融资难题，县工商联积极搭建政银企平台。组织召开政银企对接会，邀请多部门协同参与， 10家银行机构负责人与35家中小微企业代表聚焦破解企业融资堵点，推动政银企三方开展对接。协调银 行为企业量身定制个性化金融服务方案，4家银行与5家企业现场签约，签约金额达1.5亿元，合作项目 覆盖粮油储备、绿色农业、制药科技等重点领域，为产业发展注入金融"活水"。 转自：中华工商时报 依兰县工商联充分发挥桥梁纽带作用，引导民营经济人士健康成长，推动县域民营经济高质量发展。 （来源：中华工商时报） ...

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer 30% equity stake in its subsidiary, China Medical Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (referred to as "China Medical Bristol-Myers Squibb"), through a public listing with a minimum transfer price of 1.023 billion yuan [1][2] Group 1: Transaction Details - The transfer price is based on the previous equity disposal plan by Bristol-Myers Squibb, which aimed to sell its 60% stake in China Medical Bristol-Myers Squibb for approximately 480 million USD, equating to 1.44 billion USD for Shanghai Pharmaceuticals' 30% stake [1] - The transaction will result in Shanghai Pharmaceuticals no longer holding any equity in China Medical Bristol-Myers Squibb if completed successfully [1] Group 2: Company Financials - China Medical Bristol-Myers Squibb, established in 1982, has a registered capital of 18.44 million USD and operates in the pharmaceutical manufacturing sector [2] - For the fiscal year 2024 and the first three quarters of 2025, the company reported revenues of 1.795 billion yuan and 1.096 billion yuan, with net profits of 248 million yuan and 87.11 million yuan, respectively [2] - As of September 30, 2025, the total assets of China Medical Bristol-Myers Squibb amounted to 1.262 billion yuan, with net assets of 797 million yuan [2] Group 3: Strategic Implications - The transaction is expected to maximize asset value and protect the interests of all shareholders, particularly minority shareholders [1] - Shanghai Pharmaceuticals asserts that this transaction will not significantly impact its normal operations and financial status, while also optimizing its investment structure [2]

| 辅导对象 | 成都纽瑞特医疗科技股份有限公司 | | --- | --- | | 成立日期 | 2016年4月1日 | | 注册资本 | 6806. 124 万元 法定代表人 蔡继鸣 | | 注册地址 | 四川省成都市双流区西航港经济开发区空港三路 999号 | | 控 股 股东 及持股比 伊 | 宁波梅山保税港区钮特投资管理合伙企业(有限合伙),持有公司 22. 4798%的股份 | | 行业分类 | 在其他交易场 所(申请)挂 C27-医药制造业 无 牌或上市的情 况 | | 注 | 无 | 瑞财经 刘治颖 1月29日，成都纽瑞特医疗科技股份有限公司（以下简称：纽瑞特医疗）在四川证监局完 成IPO辅导备案，拟A股上市，辅导机构为国泰海通证券股份有限公司。 纽瑞特医疗成立于2016年4月，法定代表人为蔡继鸣，注册资本为6806.12万元，致力于医用同位素和放 射性药品的创新研发、生产及商业化。 公司在研多款创新产品。包括钇[90Y]炭微球注射液、核素偶联生物单抗/ 多肽等产品。主要用于诊断和 治疗肝癌、胰腺癌、淋巴癌、甲状腺癌、前列腺癌、肺癌等高发癌症。 纽瑞特医疗控股股东为宁波梅山保税港区钮特投资管理 ...

官网显示，纽瑞特医疗创始团队包括钱积惠、李茂良、蔡继鸣。目前，钱积惠、李茂良担任公司名誉董 事长，蔡继鸣担任公司董事长、总裁。 钱积惠于2016年联合创立成都纽瑞特医疗科技有限公司，自公司成立以来担任第一届、第二届董事会董 事、战略委员会主任。钱积惠毕业于哈尔滨工业大学，研究员级高级工程师。曾担任中国核动力研究设 计院院长，并曾两次赴联合国国际原子能机构任职，任副总干事长达10年。曾兼任国家核安全局专家委 员会委员、国防科工局科技委高级顾问、中核集团科技委高级顾问、清华大学核能研究院客座教授等职 务。 | 辅导对象 | 成都纽瑞特医疗科技股份有限公司 | | --- | --- | | 成立日期 | 2016年4月1日 | | 注册资本 | 6806. 124 万元 法定代表人 蔡继鸣 | | 注册地址 | 四川省成都市双流区西航港经济开发区空港三路 999号 | | 控 股 股东 及持股比 伊 | 宁波梅山保税港区钮特投资管理合伙企业(有限合伙),持有公司 22. 4798%的股份 | | 行业分类 | 在其他交易场 所(申请)挂 C27-医药制造业 无 牌或上市的情 况 | | 注 | 无 | 瑞财经 刘 ...

系列利好彰显发展势能——融入服务全国统一大市场建设取得突破，成功入选国家要素市场化配置 综合改革十个试点城市之一，是入选的唯一北方省会城市；创新动能持续增强，揭牌成立中原科技城科 创联盟、哈工大郑州高等研究院；开放活力充足，郑州机场货邮吞吐量超100万吨、成为全球航空货 运"百万吨俱乐部"成员。 城市核心竞争力同步攀升。数据显示，2025年全市新增经营主体13.78万户，市场经营主体总量达 223.86万户，全省经济首位度达22.9%。截至目前，"郑聚英才计划"吸引来郑留郑大学生超100万人，人 才总量突破320万人；城市净流入人口持续居全国城市前列，常住人口突破1300万人，规模居全国城市 第十位；全市共有国家级研发平台68家、全国重点实验室17家。 数据或能稍见端倪——2025年，全市规上工业增加值同比增长9%。工业投资实现17.9%的高速增 长，彰显强势后劲。2025年1~11月全市规模以上服务业营业收入同比增长10.1%，同比加快4.3个百分 点。消费市场不乏亮点，新能源汽车零售额增长17.1%，升级类商品如照相器材、可穿戴智能设备、智 能手机零售额分别增长1.4倍、1.2倍、1倍。 经济向"新"性气 ...

Core Viewpoint - The article highlights the increasing credit risk concerns among convertible bond issuing companies as they disclose their 2025 annual performance forecasts, with over 20 companies attracting attention from rating agencies due to various issues including performance fluctuations and management changes [1]. Group 1: Performance Loss Triggering Rating Attention - Performance losses are a primary focus for rating agencies, with seven companies under scrutiny due to expected losses [3]. - For instance, Oujing Technology anticipates a net profit loss of between -240 million to -300 million yuan for 2025, attributed to supply-demand mismatches in the photovoltaic industry and low capacity utilization [3]. - Jiangshan Oupai also expects a net profit loss of -230 million to -180 million yuan for 2025, influenced by the deep adjustment in the real estate sector and potential asset impairment provisions totaling approximately 200 million yuan [5]. Group 2: Management or Control Changes - Changes in management or control are significant concerns for rating agencies, as seen with *ST Zhongzhuang, which underwent a change in its controlling shareholder during its restructuring process [7]. - The change in control is expected to help alleviate debt crises, but ongoing monitoring of operational capabilities and management integration is necessary [7]. - Similarly, Lianchuang Electronics is under observation due to potential changes in its controlling shareholder, which could impact its credit rating [8]. Group 3: Changes in Fundraising Direction - Changes in the direction of fundraising are also closely monitored, as they can affect a company's strategic layout and financial health [10]. - For example, Jindawei announced a change in its fundraising project to optimize its industrial layout, which will be closely watched by rating agencies [10]. - Additionally, Dier Laser plans to stop using funds for a specific project, indicating a strategic shift based on current market conditions [11].

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Group 1 - In January 2026, the A-share new stock market showed remarkable performance, with an average first-day increase of over 180% for 9 newly listed stocks [1][3][6] - The enthusiasm for new stock subscriptions has risen, with public and private funds participating in offline placements, totaling over 1.5 billion yuan, with public institutions accounting for more than 1.2 billion yuan [1][7] - The newly listed stocks include companies from various sectors, primarily manufacturing, with notable mentions being Hengyun Chang and Zhenstone Co., which are highly favored by institutions [4][8] Group 2 - The average first-day increase for the 9 new stocks exceeded 187%, with Hengyun Chang and Kema Materials both experiencing surges of over 300% [6] - The issuance prices varied, with Hengyun Chang at 92.18 yuan per share and the lowest being around 11 yuan for Zhenstone and others [5] - Institutional participation in new stock subscriptions is driven by the low-risk, quick-return nature of offline placements, especially in high-growth sectors like technology and healthcare [10]

报告提到，"十四五"期间，云南省地区生产总值突破3万亿元、年均增长4.7%，人均地区生产总值超1万 美元。 2025年，云南省完成地区生产总值32765亿元、增长4.1%，规模以上工业增加值增长4.5%，第一、第三 产业增加值分别增长3.1%、5.1%，社会消费品零售总额增长2.4%，货物贸易进出口总额增长10.2%，地 方一般公共预算收入增长2.3%、支出首次超过7000亿元，城镇调查失业率均值5.2%，居民人均可支配 收入增长4.6%。 2026年，云南省经济社会发展的主要预期目标为：地区生产总值增长4.5%左右，产业投资占比保持在 50%以上，地方一般公共预算收入增长2%，城镇调查失业率5.5%以内，城镇新增就业50万人以上，居 民人均可支配收入增长与经济增长同步，粮食总产量稳定在1955万吨以上，单位地区生产总值二氧化碳 排放降低完成经国家审核衔接后确定的目标。 云南省今年将具体抓好9个方面工作。其中包括突出重点领域改革。推进要素市场化配置改革。完善容 量电价机制，有效衔接电力市场、绿证市场、碳市场。健全用水权交易制度体系。深入整治"内卷式"竞 争。进一步深化国资国企改革，构建省属企业"1+N+X"规 ...

Market Overview - The Hang Seng Index closed at 26,776 points, down 2.2%, while the Hang Seng China Enterprises Index fell 2.5% to 9,080 points[1] - Total turnover in the Hong Kong stock market was HKD 347.9 billion, a 15.4% increase from HKD 301.6 billion last Friday[1] - The materials, energy, and healthcare indices dropped by 6.0%, 4.0%, and 3.5% respectively, while consumer staples, utilities, and financials saw smaller declines of 0.2%, 1.1%, and 1.6%[1] Stock Performance - Sands China (1928 HK) and Lenovo Group (992 HK) led the blue-chip gainers, rising by 4.1% and 1.8% respectively[1] - BYD Company (1211 HK) and China Unicom (762 HK) were the biggest losers, falling by 6.9% and 6.3% respectively[1] Commodity Prices - Oil prices decreased from USD 65 to approximately USD 62, while gold prices fell from USD 5,400 to around USD 4,700[2] - The decline in commodity prices is attributed to reduced geopolitical risks and expectations of limited interest rate cuts by the Federal Reserve[2] Economic Indicators - The ISM Manufacturing PMI for January in the U.S. was reported at 52.6, exceeding December's 47.9 and the market forecast of 48.3[3] - In mainland China, the transaction volume of new homes in 30 major cities reached 1.48 million square meters, a year-on-year increase of 983.8% due to last year's Spring Festival holiday[3] Industry Insights - Macau's gaming revenue for January was AUD 22.63 billion, up 24.0% year-on-year and 8% month-on-month, exceeding market expectations[4] - The healthcare index in Hong Kong fell by 3.5%, with Rongchang Bio (9995 HK) expecting a revenue increase of 89% to RMB 3.25 billion, significantly above market expectations[4] Energy Sector - The energy sector, particularly thermal power and electrical equipment stocks, saw significant declines, with Huaneng International (902 HK) down 6.8%[5] - Recent policy changes by the National Development and Reform Commission regarding electricity pricing have raised concerns in the market, despite potential long-term benefits[5]